A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)

Inclusion criteria: * Chronic Atopic Dermatitis (AD), according to American Academy of Dermatology Consensus Criteria with onset of symptoms at least 1 year prior to the screening visit * Eczema Area and Severity Index (EASI) score greater than and equal to (\>=) 16 at the screening and baseline visits * Validated investigator global assessment for AD (vIGA-AD) score \>= 3 at the screening and baseline visits * \>= 10% body surface area (BSA) of AD involvement at the screening and baseline visits * Baseline Peak Pruritus Numeric(al) Rating Scale (PP-NRS) average score of \>=4 * Documented history (within 6 months before screening) of either inadequate response or inadvisability to topical treatments, or inadequate response to systemic therapies (within 12 months before screening) * Participant has applied a moisturizer at least once daily for at least 7 days before the baseline visit Exclusion criteria: * Experienced primary efficacy failure (no response within 16 weeks) or an adverse event (AE) requiring discontinuation related to agents (eg, severe ocular surface disease, dupilumab-associated facial redness) inhibiting IL-4Rα, IL-4, and/or IL-13 signaling (eg, dupilumab, lebrikizumab, or tralokinumab) * Participant is pregnant or breastfeeding, or planning to become pregnant or breastfeed during the study * Active skin disease other than AD including eczema herpeticum, molluscum contagiosum, impetigo, psoriasis or has any other ongoing significant skin condition includin…